LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

177.85 -0.34

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

173.04

Massimo

178.86

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

EPS

2.43

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+14.46% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

107M

8B

Apertura precedente

178.19

Chiusura precedente

177.85

Notizie sul Sentiment di mercato

By Acuity

50%

50%

155 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 mar 2026, 23:41 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mar 2026, 23:37 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mar 2026, 23:26 UTC

Principali Notizie su Eventi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mar 2026, 22:41 UTC

Discorsi di Mercato

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mar 2026, 22:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:32 UTC

Discorsi di Mercato

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mar 2026, 22:21 UTC

Discorsi di Mercato

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mar 2026, 22:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 mar 2026, 22:11 UTC

Discorsi di Mercato

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mar 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mar 2026, 22:06 UTC

Discorsi di Mercato

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mar 2026, 22:00 UTC

Discorsi di Mercato
Utili

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:00 UTC

Discorsi di Mercato
Utili

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Energy & Utilities Roundup: Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

2 mar 2026, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mar 2026, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mar 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 21:17 UTC

Principali Notizie su Eventi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mar 2026, 20:44 UTC

Utili

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:43 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2 mar 2026, 20:28 UTC

Utili

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mar 2026, 20:25 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mar 2026, 20:24 UTC

Utili

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 20:12 UTC

Principali Notizie su Eventi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mar 2026, 20:08 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 20:08 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mar 2026, 20:05 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

14.46% in crescita

Previsioni per 12 mesi

Media 204.3 USD  14.46%

Alto 265 USD

Basso 175 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

155 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat